Editorial on the Research Topic Primary Immunodeficiencies Worldwide
The field of Primary Immunodeficiencies (PID) is growing fast. Over 400 diseases are defined and characterized by recurrent or chronic infections, autoimmunity, allergy, inflammation, or cancer as a consequence of genetic alterations affecting the immune system (1). The overall incidence of PID is around 1:10,000 and the majority presents early in childhood. Over the past decades, there has been an enormous increase in understanding of disease pathology, as well as clinical expertise and patient awareness worldwide, as a result of educational initiatives and scientific meetings by medical societies, supporting agencies, and patient associations.
Humans are genetically heterogeneous, and the environmental characteristics and social habits differ dramatically in the several geographic regions of the world. Consequently, the prevalence and distribution of the nine groups of primary immunodeficiencies vary worldwide, and the clinical profile of a particular PID will also vary.
Most of the literature and discoveries about Primary Immunodeficiencies come from North America and Europe and refer to these geographical areas. This Frontiers Research Topic was developed to bring together original clinical and basic research from authors representing various geographical areas to highlight challenges and developments in epidemiology, diagnosis, and treatment of Primary Immunodeficiencies worldwide.
Twenty-two articles are included in this Research Topic, and are categorized into the following types Within the context of epidemiology, several papers present and discuss infectious complications in international cohorts. It is discussed how cellular and molecular defects of the immune system predispose to invasive endemic fungal infections worldwide (Lee and Lau). Furthermore, it is shown that PID patients excrete poliovirus for extended periods (Macklin et al.) , and that these may form a reservoir that forms a risk to poliovirus eradication strategies (Aghamohammadi et al. The most optimal timing of PID diagnosis is before disease presentation and that is aimed at in newborn screening programs. A lot of experience has been obtained with the T cell receptor excision circle (TREC) assay in the USA (Thakar et al.), and many countries worldwide, including Israel, have now adopted it (Rechavi et al.).
Still, more insights into PID pathogenesis and genetics are needed. Diagnosis of antibody deficiency remains challenging, especially in the context of normal total IgG serum levels (Sorensen), and this can result in substantial diagnostic delays (Slade et al.). Functional assays for diagnostics require more insights into disease pathogenesis, and this lies at the heart of basic research into PID. The ultimate focus of the Research Topic concerns treatment of PID. Immunoglobulin replacement therapy is already provided for over 60 years to supplement IgG, but has additional immunomodulatory roles that are still not completely understood (Quinti and Mitrevski), and might warrant the use even beyond antibody deficiency. More recently developed biologicals will hold even more promise over the coming years (Quinti and Mitrevski). Corrective therapy would be ultimate form of treatment, and hematopoietic stem cell transplantation is currently more widely applied in combined immunodeficiencies and in immune dysregulation disorders. Although the rarity of specific PIDs could hamper clinical trials, the genetic definition of disease should provide the best rationale for compassionate access to enable precision medicine.
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